Adam Kilgore has a story about Bryce Harper and the way he takes care of his body. His only apparent vice: ice cream and occasional Starbucks drinks. But otherwise, his body is a temple. That goes for even the occasional beer now that he’s 21. It even goes for certain drugs and treatments that are commonplace and accepted in baseball.
Last year it was suggested that he take cortisone to deal with his knee injury. He didn’t want to and put it off. Eventually he did. But:
Looking back, Harper regrets taking the cortisone. He found the effects fleeting and the risk unworthy. He plans to never use cortisone again.
“I don’t think it really changed me,” Harper said. “I was still hurt. It gave me a boost for a week, where I felt, ‘Hey, I feel good.’ But then a couple days later, it was like, ‘Ack, this sucks.’ I’ll probably never do that again. I don’t like putting that stuff in my body. I don’t want to. I’m just not a big fan of it.”
He says he should have had the surgery he had in the offseason as soon as the injury happened. He goes on to talk about things relating to playing through pain, which sound like they contrast a bit with what you usually hear in baseball about playing through pain (you should do it) vs. playing through injury (you should not).
Obviously you’d rather have a guy erring on the side Harper is erring on — as opposed to erring on the side of excess — when it comes to junk food, drink and performance-enhancing drugs. How many guys aren’t at their best because they’re playing with hangovers or lugging around extra weight? But that Harper’s aim to keep his system pure might come into conflict with the team’s medical advice is potentially troublesome.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.